Kidney cancer is the abnormal growth of cells in the kidney tissue. As with all cancers, early detection is the key to a successful cure. Alfa Cytology is a world leader in the research of cancer. With our extensive experience and advanced platform, we can provide the best solutions for kidney cancer.
Introduction to Kidney Cancer
Kidney cancer accounts for about 3.7% of all cancers in the United States. More than 62,000 Americans are diagnosed with kidney cancer each year. The risk of kidney cancer increases with age. It is most common in people aged 65 to 74. Men are twice as likely to develop kidney cancer as women. There are different types of kidney cancer.
Renal Cell Carcinoma (RCC)
RCC is the most common form of kidney cancer in adults, accounting for 85% of all kidney cancers. It starts in the lining cells of the renal tubules. The most common type of RCC is clear cell renal cell carcinoma (ccRCC).
Transitional Cell Carcinoma
Transitional cell carcinoma accounts for 6 to 7 percent of all kidney cancers. This cancer usually starts in the area where the ureter connects to the main part of the kidney, and can also occur in the ureter or bladder.
Nephrosarcoma
This is the least common form of kidney cancer, accounting for only 1% of kidney cancer cases. It starts in the connective tissue of the kidneys and can spread to nearby organs and bones if left untreated.
Therapy Development for Kidney Cancer
Kidney cancer therapy depends on the stage and grade of the tumor, as well as age and overall health. Therapy options include surgery, ablation, radiation therapy, targeted drug therapy, immunotherapy, and chemotherapy. Radiation therapy is most commonly used to relieve symptoms of kidney cancer, such as pain. Chemotherapy is not the standard therapy for kidney cancer and is usually only effective after immunotherapy and targeted drug therapy.
| Targets |
Therapeutics |
Company |
Molecule Type |
Phase |
| LAG-3 |
Favezelimab + pembrolizumab (MK-4280a) |
Merck |
Monoclonal antibody |
|
| CAIX |
TLX250 |
Telix |
Antibody-drug conjugate |
|
| Bcl-2 |
Venclexta (RG7601) |
Roche |
Small molecule |
|
| IL-6 |
Enspryng (RG6168) |
Roche |
Monoclonal antibody |
|
Our Services
Developing effective therapies for kidney cancer faces several challenges. Kidney cancer is a heterogeneous disease that hinders the identification of universal targets. In addition, kidney cancer has shown resistance to traditional therapies, hence the need for targeted therapies and immunotherapies. In this regard, Alfa Cytology is working on providing one-stop solutions for kidney cancer, including but not limited to the following.
Models of Kidney Cancer
As a provider of comprehensive scientific research services, Alfa Cytology offers a range of animal model options specifically designed for kidney cancer research. These models are crucial in understanding disease mechanisms, evaluating therapy outcomes, and developing new therapy strategies.
Cell Line
- 786-O cell line model
- ACHN cell line model
- CAKI-1 cell line model
- A498 cell line model
Animal Model
- loxP bilateral gene excision model
- VHL-mutations models
- TP53-mutations models
- RB1-mutations models
Alfa Cytology is committed to the research and therapy development for kidney cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for kidney cancer. If you are interested in our service, please contact us for more information.
For research use only.
Related Services
